Aminopenicillins——疾病临床药理学和使用。

文章的细节

引用

复制到剪贴板

Neu HC

Aminopenicillins——疾病临床药理学和使用。

Int中国Biopharm杂志》1975年3月,11 (2):132 - 44。

PubMed ID

1095502 (在PubMed

]

文摘

氨苄青霉素在1961年引入管理治疗各种感染了口腔和肠胃外的意思。口服中耳炎等上呼吸道感染,支气管炎,肺炎回应高成功率,因为涉及的微生物对氨苄青霉素仍敏感。同样,门诊病人尿路感染引起的大肠杆菌,变形杆菌,和enterococci治愈。伤寒可能会用氨苄青霉素治疗,但志贺氏菌病已成为耐火耐药菌株的发展。氨苄青霉素扮演了一个重要角色在淋病的治疗。肠胃外的氨苄青霉素仍然是一个主要的治疗嗜血杆菌脑膜炎,但最近出现的氨苄青霉素耐药菌株可能成为一个严重的问题。大量的衍生品和氨苄青霉素已经开发的类似物。在化合物中,缩酮氨苄青霉素,metampicillin pivampicillin体内水解产生氨苄青霉素,只有pivampicillin似乎提供优势的母体化合物。血液是同等剂量的氨苄青霉素的两倍。然而,更多的与氨苄青霉素在临床情况下是必要的。 The other analogues of ampicillin are epicillin, cyclacillin and amoxicillin. Epicillin has no superiority to ampicillin, and the cyclacillin data do not show clear superiority over ampicillin in spite of initially high blood levels, since the compound is less active and so rapidly cleared from the body. Amoxicillin, on the other hand, has been shown to have it vitro activity equal to ampicillin and to produce higher blood levels for a longer period of time. Clinical studies have substantiated efficacy in treatment of otitis media, pharyngitis, bronchitis, pneumonitis, and urinary tract infections at doses half those of ampicillin. It has been effective in gonorrhoea and typhoid, but not in shigellosis. It would seem that to date only pivampicillin and amoxicillin, particularly the later, should be considered as replacements of ampicillin in oral therapy.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
缩酮氨苄青霉素	Penicillin-binding蛋白1	蛋白质	肺炎链球菌(写明ATCC baa应变- 255 / R6)	是的	抑制剂	细节
缩酮氨苄青霉素	Penicillin-binding蛋白质1 b	蛋白质	肺炎链球菌(写明ATCC baa应变- 255 / R6)	是的	抑制剂	细节
缩酮氨苄青霉素	Penicillin-binding蛋白2	蛋白质	肺炎链球菌(写明ATCC baa应变- 255 / R6)	是的	抑制剂	细节
缩酮氨苄青霉素	Penicillin-binding蛋白质2 b	蛋白质	肺炎链球菌(写明ATCC baa应变- 255 / R6)	是的	抑制剂	细节
缩酮氨苄青霉素	Penicillin-binding蛋白3	蛋白质	链球菌引起的肺炎	是的	抑制剂	细节